AMENDMENTS

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

1. (Currently amended) A milnacipran formulation that provides pulsatile release of milnacipran wherein the formulation comprises:

   (a) an immediate release **solid** dosage unit comprising a first dose of milnacipran that is released substantially immediately following oral administration of the formulation to a patient, resulting in a first plasma level peak at a time between approximately 0.05 hours to less than **approximately** 3 hours following oral administration; **and**

   (b) a ~~first~~ delayed release **solid** dosage unit comprising **a delayed release polymer and** a second dose of milnacipran **that is released 3 to 10 hours following oral administration of the formulation;** ~~resulting in a second plasma level peak at a time of more than 3 hours to less than 14 hours following oral administration of the formulation; and optionally~~

   ~~(c) a second delayed release dosage unit comprising a third dose of milnacipran resulting in a third plasma level peak at a time between approximately 5 hours to less than 18 hours following oral administration of the formulation; and~~

   wherein there is a lag time where there is substantially no release of milnacipran between the release of **milnacipran from** the immediate release **solid** dosage unit and the release of **milnacipran from** the ~~first~~ delayed release **solid** dosage unit**; and**

   wherein the formulation produces a therapeutic effect over 24 hours when administered to a patient in need thereof with diminished incidence or reduced intensity relative to side effects resulting from administration of the same dose of milnacipran administered in an immediate release formulation.

2. (Cancelled).

3. (Currently amended) The milnacipran formulation according to ~~claim 2~~**claim 1**, wherein the side effects are nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, or insomnia.

4. (Cancelled).

5. (Cancelled).

6. (Previously presented) The milnacipran formulation according to claim 1 providing milnacipran blood plasma levels having a C_{max} below approximately 3000 ng/ml.

7. (Previously presented) The milnacipran formulation according to claim 6 providing milnacipran blood plasma levels having a C_{max} below approximately 2000 ng/ml.

8. (Previously presented) The milnacipran formulation according to claim 6 providing milnacipran blood plasma levels having a C_{max} below approximately 1000 ng/ml.

9. (Previously presented) The milnacipran formulation according to claim 1 further comprising at least one other compound selected from the group consisting of analgesics, anti-inflammatory drugs, antipyretics, antidepressants, antiepileptics, antihistamines, antimigraine drugs, antimuscarinics, anxioltyics, sedatives, hypnotics, antipsychotics, bronchodilators, anti asthma drugs, cardiovascular drugs, corticosteroids, dopaminergics, electrolytes, gastro-intestinal drugs, muscle relaxants, nutritional agents, vitamins, parasympathomimetics, stimulants, anorectics, and anti-narcoleptics.

10. (Original) The milnacipran formulation according to claim 9 comprising one or more compounds selected from the group consisting of aceclofenac, acetaminophen, adomexetine, almotriptan, alprazolam, amantadine, amcinonide, aminocyclopropane, amitriptyline, amolodipine, amoxapine, amphetamine, aripiprazole, aspirin, atomoxetine, azasetron, azatadine, beclomethasone, benactyzine, benoxaprofen, bermoprofen, betamethasone, bicifadine, bromocriptine, budesonide, buprenorphine, bupropion, buspirone, butorphanol, butriptyline, caffeine, carbamazepine, carbidopa, carisoprodol, celecoxib, chlordiazepoxide, chlorpromazine, choline salicylate, citalopram, clomipramine, clonazepam, clonidine, clonitazene, clorazepate, clotiazepam, cloxazolam, clozapine, codeine, corticosterone, cortisone, cyclobenzaprine, cyproheptadine, demexiptiline, desipramine, desomorphine, dexamethasone, dexanabinol, dextroamphetamine sulfate, dextromoramide, dextropropoxyphene, dezocine, diazepam, dibenzepin, diclofenac sodium, diflunisal, dihydrocodeine, dihydroergotamine, dihydromorphine, dimetacrine, divalproxex, dizatriptan, dolasetron, donepezil, dothiepin, doxepin, duloxetine, ergotamine, escitalopram, estazolam, ethosuximide, etodolac, femoxetine, fenamates, fenoprofen, fentanyl, fludiazepam, fluoxetine, fluphenazine, flurazepam, flurbiprofen, flutazolam, fluvoxamine, frovatriptan, gabapentin, galantamine, gepirone, ginko bilboa, granisetron, haloperidol, huperzine A, hydrocodone, hydrocortisone, hydromorphone, hydroxyzine, ibuprofen, imipramine, indiplon, indomethacin, indoprofen, iprindole, ipsapirone, ketaserin, ketoprofen, ketorolac, lesopitron, levodopa, lipase, lofepramine, lorazepam, loxapine, maprotiline, mazindol, mefenamic acid, melatonin, melitracen, memantine, meperidine, meprobamate, mesalamine, metapramine, metaxalone, methadone, methadone, methamphetamine, methocarbamol, methyldopa, methylphenidate, methylsalicylate, methysergid(e), metoclopramide, mianserin, mifepristone, milnacipran, minaprine, mirtazapine, moclobemide, modafinil, molindone, morphine, morphine hydrochloride, nabumetone, nadolol, naproxen, naratriptan, nefazodone, neurontin, nomifensine, nortriptyline, olanzapine, olsalazine, ondansetron, opipramol, orphenadrine, oxaflozane, oxaprazin, oxazepam, oxitriptan, oxycodone, oxymorphone, pancrelipase, parecoxib, paroxetine, pemoline, pentazocine, pepsin, perphenazine, phenacetin, phendimetrazine, phenmetrazine, phenylbutazone, phenytoin, phosphatidylserine, pimozide, pirlindole,

piroxicam, pizotifen, pizotyline, pramipexole, prednisolone, prednisone, pregabalin, propanolol, propizepine, propoxyphene, protriptyline, quazepam, quinupramine, reboxitine, reserpine, risperidone, ritanserin, rivastigmine, rizatriptan, rofecoxib, ropinirole, rotigotine, salsalate, sertraline, sibutramine, sildenafil, sulfasalazine, sulindac, sumatriptan, tacrine, temazepam, tetrabenozine, thiazides, thioridazine, thiothixene, tiapride, tiasipirone, tizanidine, tofenacin, tolmetin, toloxatone, topiramate, tramadol, trazodone, triazolam, trifluoperazine, trimethobenzamide, trimipramine, tropisetron, valdecoxib, valproic acid, venlafaxine, viloxazine, vitamin E, zimeldine, ziprasidone, zolmitriptan, zolpidem, zopiclone and isomers, salts, and combinations thereof.

11. (Original) The milnacipran formulation according to claim 1, wherein the milnacipran is in the form of a therapeutically equivalent dose of dextrogyral or levrogyral enantiomers of the milnacipran or pharmaceutically acceptable salts thereof.

12. (Original) The milnacipran formulation according to claim 1, wherein the milnacipran is in the form of a therapeutically equivalent dose of a mixture of milnacipran enantiomers or pharmaceutically acceptable salts thereof.

13. (Cancelled).

14. (Previously presented) The milnacipran formulation according to claim 1, wherein the milnacipran is in the form of a therapeutically equivalent dose of para-hydroxy-milnacipran (F2782), individual enantiomers of para-hydroxy-milnacipran, mixtures of enantiomers of para-hydroxy-milnacipran, or pharmaceutically acceptable salts thereof.

15. (Cancelled).

16. (Previously presented) The milnacipran formulation according to claim 1, wherein the formulation comprises 25 to 500 mg of milnacipran.

17. (Previously presented) The milnacipran formulation according to claim 1, wherein the formulation comprises 200 to 500 mg of milnacipran.

18. (Cancelled).

19. (Previously presented) The milnacipran formulation according to claim 1 wherein the immediate release dosage unit and the first delayed release dosage unit are each in the form of a mixture of beads or particles wherein the particles release drug at different times.

20. (Original) A kit comprising the milnacipran formulation of claim 1.

21. (Original) The kit of claim 20 comprising different dosage units of milnacipran to allow for dosage escalation.

22. (Cancelled).

23. (Cancelled).

24. (Cancelled).

25. (Cancelled).

26. (Cancelled).

27. (Cancelled).

28. (Previously presented) The milnacipran formulation according to claim 1, wherein the immediate release dosage unit and the first delayed release dosage unit are each in the form of a tablet, wherein each tablet releases drug at different times.

29. (New) A milnacipran formulation that provides pulsatile release of milnacipran wherein the formulation comprises:

(a) an uncoated immediate release tablet comprising from 25 to 75 mg milnacipran, where the milnacipran in the immediate release tablet is released substantially immediately following oral administration of the formulation to a patient resulting in a first plasma level peak at a time between approximately 0.05 hours to less than approximately 3 hours following oral administration; and

(b) a delayed release tablet comprising from 25 to 75 mg milnacipran and a coating comprising one or more methacrylic acid-methyl methacrylate copolymers soluble at pH 6.0 or above, where the dose of milnacipran in the first delayed release tablet is released approximately 3 to 10 hours following oral administration of the formulation;

wherein there is a lag time where there is substantially no release of milnacipran between the release of milnacipran from the immediate release tablet and the release of milnacipran from the delayed release tablet; and

wherein the formulation produces a therapeutic effect over 24 hours when administered to a patient in need thereof with diminished incidence or reduced intensity relative to side effects resulting from administration of the same dose of milnacipran administered in an immediate release formulation.

30. (New) The milnacipran formulation of claim 1, wherein the formulation further comprises:

(c) a second delayed release solid dosage unit comprising a second delayed release polymer and a third dose of milnacipran that is released 5 to 18 hours following oral administration of the formulation;

wherein there is a lag time where there is substantially no release of milnacipran between the release of milnacipran from the first delayed release solid dosage unit and the release of milnacipran from the second delayed release solid dosage unit.